Published in

BioMed Central, BMC Cancer, 1(14), 2014

DOI: 10.1186/1471-2407-14-619

Links

Tools

Export citation

Search in Google Scholar

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach

Journal article published in 2014 by Tiziana Comito, Luca Cozzi, Elena Clerici, Maria Concetta Campisi, Rocco Luca Emanuele Liardo ORCID, Pierina Navarria, AnnaMaria Ascolese, Angelo Tozzi, Cristina Iftode, Fiorenza De Rose, Elisa Villa, Nicola Personeni, Lorenza Rimassa ORCID, Armando Santoro ORCID, Antonella Fogliata and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Background To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer. Methods 82 patients with 1–3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity. Results Median follow-up was 24 months (range 3–47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with 3 cm ( p  3 toxicity. Conclusions SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.